Al Altomari: Yes. We are €“ think of that as a formulary. We are in a preferred position on their formulary. It’s going to be up to them how to manage the patient. Amy has been really sensitive to patients. Like if a woman is on Xulane and she is happy, she should stay. She should stay. I mean we really €“ that’s really some of behind the scenes things we have been talking about. Now, we hope a new patient comes in, we get that patient. But our €“ we are in a preferred position, which is great. We are a good partner with them. Amy works hand-in-hand with them. But we say, look, do what’s right for the patient. In the long run, we will benefit. So, that’s kind of in our philosophy.
Amy Welsh: Definitely.
Al Altomari: So, it’s not going to be black and white like in some of the Planned Parenthood are in right falling off . So, that’s a little different situation. This will be kind of €“ as Amy was saying, we will grow into it.
Oren Livnat: And I guess just one last one on retail long-term. Has there been any noticeable tailwind or change in payer coverage or payer compliance with coverage mandates with regards to Twirla or any other contraceptives that you have seen since the White House started to bring some real heat on to the payers?
Al Altomari: The answer is yes. I mean Amy and I review that data a lot. I mean what we see is all boats are rising. In the early days, kind of the headwinds would require doctors doing these letters of prior auth, as we talked you through, Oren, or letters of medical necessity. And they were even being stopped, which is what we thought was wrong. We are seeing them go through. So, there is less friction, if you will, on the script. The scripts have a better chance of getting filled. Another reason we like in Nurx and specialty pharm is that they can talk to patients through and say, hey, it might take us a week or two weeks to get this paperwork in. In the meantime, here is a sample. So, the answer is yes, and we see it across all brands, which is great.
When €“ your question on formulary, no, we haven’t seen much movement in formulary. So doctors, we still think, the big win for us. Imagine today, we get the formulary wins, Oren. The wins €“ what we are doing right now is remarkable, I believe in retail. But formularies, I think a whole different game if we can unlock the formularies.
Oren Livnat: Sure. So, if there is some improvement on the compliance with letters of medical necessity or whatever €“ the waiver, so to speak, for ACA, is it an opportunity for you to go back? I imagine early on some people wrote, especially when you had a broader footprint with sales, some people wrote prescriptions and were probably inappropriately rejected by payers. And I can only imagine that’s a tough first impression for a doctor to have with any product launch. Do you have the opportunity to go back and revisit as this landscape has improved a little bit to some of these doctors and say, hey, I know you tried and failed before, but try again?
